Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. The economic burden of Crohn's disease in Europe: findings from a systematic literature review. Poster presented at the 2019 27th United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:906.
Hallas J, Margulis AV, Pottegard A, Kristiansen NS, Atsma WJ, Appenteng K, de Vogel S, Kaye JA, Perez-Gutthann S, Arana A. Incidence of common cancers in users of antimuscarinic medications for overactive bladder: a Danish nationwide cohort study. Basic Clin Pharmacol Toxicol. 2018 Jun;122(6):612-9. doi: 10.1111/bcpt.12965
Franklin JM, Dejene S, Huybrechts KF, Wang SV, Kulldorff M, Rothman KJ. A bias in the evaluation of bias comparing randomized trials with nonexperimental studies. Epidemiol Methods. 2017 Apr;6(1):20160018.. doi: 10.1515/em-2016-0018.
Camilleri M, Lembo AJ, Lavins BJ, Macdougall JE, Carson RT, Williams VSL, Nelson LM, Shiff SJ, Currie MG, Kurtz CB, Johnston JM. Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS-C. United European Gastroenterol J. 2015 Feb 3;3(1):53-62. doi: 10.1177/2050640614555946
Strickland A, Brogan AJ, Krauss J, Martindale R, Cresci G. Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation. J Parenter Enter Nutr. 2005 Jan 1;29(1 Suppl):S81-91.